Physician profile
Deniz Kesebir
NPI 1497914576
$5,829.89
in general payments reported to CMS, 2019-2025
11 companies · $1,619 in 2025
The $1,619 reported for 2025 was more than what 92% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $236 · 2021: $479 · 2022: $464 · 2023: $1,471 · 2024: $1,273 · 2025: $1,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,263 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,263.22 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,154.52 | 2019-2025 | Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $1,370.16 | 2020-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $268.59 | 2022-2025 | Dupixent |
| Genzyme Corporation | $208.44 | 2023-2025 | |
| Genentech USA, INC. | $161.76 | 2019-2021 | |
| Amgen INC. | $153.84 | 2023-2024 | Tezspire |
| Ipsen Biopharmaceuticals, INC | $150.00 | 2024 | Bylvay |
| Abbvie INC. | $145.02 | 2024 | |
| Baxter Healthcare | $100.05 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Novartis Pharmaceuticals Corporation | $17.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deniz Kesebir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.